Start Date
August 3, 2023
Primary Completion Date
August 3, 2023
Study Completion Date
August 3, 2023
MabionCD20 (candidate biosimilar to rituximab)
Intravenous infusion, 10 mg/ml concentrate, 500 ml
MabThera®
Intravenous infusion, 10 mg/ml concentrate, 500 ml
Rituxan®
Intravenous infusion, 10 mg/ml concentrate, 500 ml